Published in Oncotarget on May 03, 2016
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer (2006) 6.76
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 3.65
To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol (1998) 2.81
Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle (2010) 2.61
Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res (2009) 2.28
Does tumour dormancy offer a therapeutic target? Nat Rev Cancer (2010) 2.19
DE-Cadherin is required for intercellular motility during Drosophila oogenesis. J Cell Biol (1999) 2.18
Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer (2006) 2.11
EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget (2015) 1.92
Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res (2004) 1.84
Mechanisms governing metastatic dormancy and reactivation. Cell (2013) 1.81
Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res (2012) 1.57
Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature (2015) 1.53
Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer (2014) 1.51
p53 and chemosensitivity. Ann Oncol (1999) 1.42
Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One (2012) 1.41
Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res (1998) 1.41
Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett (2008) 1.33
p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene (2007) 1.21
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett (2013) 1.18
Loss of E-cadherin expression associated with lymph node metastases in small breast carcinomas. Virchows Arch (1997) 1.12
Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun (2011) 1.10
p53- and p21-dependent premature APC/C-Cdh1 activation in G2 is part of the long-term response to genotoxic stress. Oncogene (2010) 1.07
Cdh1-anaphase-promoting complex targets Skp2 for destruction in transforming growth factor beta-induced growth inhibition. Mol Cell Biol (2007) 1.07
APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity. Cell Cycle (2010) 1.06
Tumor dormancy and cancer stem cells: two sides of the same coin? Adv Exp Med Biol (2013) 1.04
Smad2 mediates Activin/Nodal signaling in mesendoderm differentiation of mouse embryonic stem cells. Cell Res (2010) 1.03
Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne) (2012) 0.96
Canonical non-homologous end joining in mitosis induces genome instability and is suppressed by M-phase-specific phosphorylation of XRCC4. PLoS Genet (2014) 0.93
Pharmacological activation of p53 in cancer cells. Curr Pharm Des (2011) 0.92
Cyclin-dependent kinase-dependent phosphorylation of Lif1 and Sae2 controls imprecise nonhomologous end joining accompanied by double-strand break resection. Genes Cells (2012) 0.92
DNA damage triggers p21WAF1-dependent Emi1 down-regulation that maintains G2 arrest. Mol Biol Cell (2009) 0.91
Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy. Cell Cycle (2013) 0.90
Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. Oncotarget (2015) 0.89
Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) (2012) 0.85
Loss of E-cadherin expression is not a prerequisite for c-erbB2-induced epithelial-mesenchymal transition. Int J Oncol (2014) 0.85
DNA double strand break repair in mitosis is suppressed by phosphorylation of XRCC4. PLoS Genet (2014) 0.84
Cadmium modifies the cell cycle and apoptotic profiles of human breast cancer cells treated with 5-fluorouracil. Int J Mol Sci (2013) 0.83
Knockdown of p53 suppresses Nanog expression in embryonic stem cells. Biochem Biophys Res Commun (2013) 0.83
Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis. Tissue Barriers (2014) 0.82
Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics (2013) 0.81
Cancer stem cells and tumor dormancy. Adv Exp Med Biol (2013) 0.80
Eukaryotic cell encystation and cancer cell dormancy: is a greater devil veiled in the details of a lesser evil? Cancer Biol Med (2015) 0.76
A marker for dormant cancer stem cells in human hepatocellular carcinoma. Gastroenterology (2011) 0.76